Sensitivity to both PI3Kβ and AKT inhibitors in PTEN null tumor cell lines is limited by re-activation of PI3K/AKT/mTORC1 signaling, with both common and unique drivers of resistance to both inhibitors. The gene discussed is AKT1; the disease is neoplasm.